2-二氟甲氧基溴苯 | 175278-33-8

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 芳香烃
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-二氟甲氧基溴苯
• 中文别名: 1-溴-2-(二氟甲氧基)苯
• 英文名称: 1-bromo-2-(difluoromethoxy)benzene
• 英文别名: 2-(Difluoromethoxy)Bromobenzene
• CAS: 175278-33-8
• 化学式: C₇H₅BrF₂O
• mdl: MFCD00221468
• 分子量: 223.017
• InChiKey: VHEICCMNYWNFQX-UHFFFAOYSA-N

物化性质

• 沸点：
  85 °C
• 密度：
  1.582
• 闪点：
  85-87°C/15mm
• 稳定性/保质期：
  避氧化物

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2909309090
• 危险类别：
  IRRITANT

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Bromo-2-(difluoromethoxy)benzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H411: Toxic to aquatic life with long lasting effects
P273: Avoid release to the environment

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Bromo-2-(difluoromethoxy)benzene
CAS number: 175278-33-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H5BrF2O
Molecular weight: 223.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-二氟甲氧基溴苯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium phosphate 、 [(di(1-adamantyl)butylphosphine)-2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate 、 potassium acetate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 4.0h， 生成 tert-butyl 3-(7-(2-(difluoromethoxy)phenyl)-8-fluoro-2-((hexahydro-1H-pyrrolizin-7a-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
  参考文献：
  名称：

  [EN] KRAS G12D INHIBITORS
  [FR] INHIBITEURS DE KRAS G12D

  摘要：

  本发明涉及抑制KRas G12D的化合物。具体地，本发明涉及抑制KRas G12D活性的化合物，包括这些化合物的药物组合物以及使用方法。

  公开号：

  WO2021041671A1
• 作为产物：
  描述：

  2-溴苯酚 、 sodium chlorodifluoroacetate 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 2-二氟甲氧基溴苯
  参考文献：
  名称：

  [EN] KRAS G12D INHIBITORS
  [FR] INHIBITEURS DE KRAS G12D

  摘要：

  本发明涉及抑制KRas G12D的化合物。具体地，本发明涉及抑制KRas G12D活性的化合物，包括这些化合物的药物组合物以及使用方法。

  公开号：

  WO2021041671A1
• 作为试剂：
  描述：

  苯乙腈 在 2-二氟甲氧基溴苯 、 2-羟基-5-甲基-3-硝基吡啶 、 strontium chloride 作用下， 以 二乙胺 为溶剂， 98.0 ℃ 、6.2 MPa 条件下， 反应 6.0h， 以92%的产率得到2-苯乙胺
  参考文献：
  名称：

  一种苯乙双胍药物中间体β-苯乙胺的合成方法

  摘要：

  本发明公开了一种苯乙双胍药物中间体β‑苯乙胺的合成方法。通过在2‑羟基‑5‑甲基‑3‑硝基吡啶、2‑二氟甲氧基溴苯和二乙胺混合溶液中，加入氯化锶粉末和苯乙腈，并在氩气保护下，进行升温、升压反应，然后降温、放出氩气，加入乙酸乙酯溶液，过滤、减压蒸馏、洗涤、重结晶，得到晶体β‑苯乙胺。该合成方法相比于背景技术中的合成方法，反应中无需通入氢气和氨气，提高了反应的安全性，收率明显提高，同时本发明提供了一种新的合成路线，为进一步提升反应收率打下了良好的基础。

  公开号：

  CN106083602A

文献信息

• HETEROCYCLIC INHIBITORS OF MCT4
  申请人：Vettore, LLC

  公开号：US20180162822A1

  公开（公告）日：2018-06-14

  Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

  本文披露了一些化合物和组合物，适用于治疗由MCT4介导的疾病，如增殖性和炎症性疾病，其结构如下所示： 还提供了在人类或动物主体中抑制MCT4活性的方法。
• Catalytic radical difluoromethoxylation of arenes and heteroarenes
  作者：Johnny W. Lee、Weijia Zheng、Cristian A. Morales-Rivera、Peng Liu、Ming-Yu Ngai

  DOI：10.1039/c8sc05390a

  日期：——

  Intermolecular C–H difluoromethoxylation of (hetero)arenes remains a long-standing and unsolved problem in organic synthesis. Herein, we report the first catalytic protocol employing a redox-active difluoromethoxylating reagent 1a and photoredox catalysts for the direct C–H difluoromethoxylation of (hetero)arenes. Our approach is operationally simple, proceeds at room temperature, and uses bench-stable

  （杂）芳烃的分子间CH-H二氟甲氧基化在有机合成中仍然是一个长期存在且尚未解决的问题。在这里，我们报道了第一个使用氧化还原活性二氟甲氧基化试剂1a和光氧化还原催化剂对（杂）芳烃进行直接CHH二氟甲氧基化的催化方案。我们的方法操作简便，可在室温下进行，并使用稳定的试剂。其温和的反应条件可耐受多种官能团和生物相关分子，从而突出了其合成用途。实验和计算研究表明，单电子转移（SET）从激发的光氧化还原催化剂到1a，形成释放OCF 2的中性自由基中间体仅氢自由基。将该自由基加到（杂）芳烃上，得到二氟甲氧基化的环己二烯基，其被氧化和去质子化，得到二氟甲氧基化的产物。
• [EN] DIFLUOROMETHOXYLATION AND TRIFLUOROMETHOXYLATION COMPOSITIONS AND METHODS FOR SYNTHESIZING SAME<br/>[FR] COMPOSITIONS DE DIFLUOROMÉTHOXYLATION ET DE TRIFLUOROMÉTHOXYLATION ET LEURS PROCÉDÉS DE SYNTHÈSE
  申请人：UNIV NEW YORK STATE RES FOUND

  公开号：WO2019168874A1

  公开（公告）日：2019-09-06

  The present invention provides a compound having the structure (I), a processing of making the compound; and a process of using the compound as a reagent for the difluoromethoxylation and trifluoromethoxylation of arenes or heteroarenes.

  本发明提供了一种具有结构（I）的化合物，制备该化合物的方法；以及将该化合物用作芳烃或杂环芳烃的二氟甲氧基化和三氟甲氧基化试剂的方法。
• Redox‐Neutral TEMPO Catalysis: Direct Radical (Hetero)Aryl C−H Di‐ and Trifluoromethoxylation
  作者：Johnny W. Lee、Sanghyun Lim、Daniel N. Maienshein、Peng Liu、Ming‐Yu Ngai

  DOI：10.1002/anie.202009490

  日期：2020.11.23

  Applications of TEMPO. catalysis for the development of redox‐neutral transformations are rare. Reported here is the first TEMPO.‐catalyzed, redox‐neutral C−H di‐ and trifluoromethoxylation of (hetero)arenes. The reaction exhibits a broad substrate scope, has high functional‐group tolerance, and can be employed for the late‐stage functionalization of complex druglike molecules. Kinetic measurements

  TEMPO 的应用。氧化还原中性转化发展的催化作用很少见。这里报道的是第一个TEMPO 。（杂）芳烃的催化氧化还原中性 C−H 二氟甲氧基化和三氟甲氧基化。该反应表现出广泛的底物范围，具有较高的官能团耐受性，可用于复杂药物分子的后期功能化。动力学测量、催化中间体的分离和重新研究、UV/Vis 研究和 DFT 计算支持了所提出的氧化 TEMPO 。/TEMPO +氧化还原催化循环。机理研究还表明Li 2 CO 3在防止催化剂失活方面发挥着重要作用。这些发现将为通过氧化还原中性 TEMPO 设计和开发新型反应提供新的见解。催化。
• FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF
  申请人：GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD.

  公开号：US20180208604A1

  公开（公告）日：2018-07-26

  Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase.

  揭示的区域融合环嘧啶化合物，以及中间体、制备方法、组合物及其用途。融合环嘧啶化合物是如下式I所示的化合物，其为互变异构体、对映异构体、顺反异构体、药学上可接受的盐、代谢物、代谢前体或其前药，上述化合物用于制备用于预防、缓解或治疗免疫系统疾病、自身免疫疾病、细胞增殖性疾病、过敏性疾病和心血管疾病中的一种或多种的药物，且该化合物对Janues激酶、FGFR激酶、FLT3激酶和Src家族激酶具有强烈的抑制作用。